Elacestrant
| CAS No. | 722533-56-4 |
|---|---|
| MDL No. | MFCD30532693 |
| MF | C30H38N2O2 |
| MW | 458.60 |
| InChI Key | SIFNOOUKXBRGGB-AREMUKBSSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Elacestrant is a tetralin derivative of 1,2,3,4-tetrahydronaphthalene, substituted with a hydroxy group at position 2 and a 2-(ethyl{4-[2-(ethylamino)ethyl]benzyl}amino)-4-methoxyphenyl group at position 6R. It is an estrogen receptor degrader indicated for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed following at least one line of endocrine therapy. It functions as an antineoplastic agent, estrogen receptor antagonist, and anti-estrogen. It is classified as a monomethoxybenzene, a tetralin, a tertiary amino compound, a secondary amino compound, a substituted aniline, and an organic hydroxy compound.
| CAS No. | 722533-56-4 |
|---|---|
| Product Name | Elacestrant |
Biological Targets
ESR1
Associated Conditions
Hot flashes·breast cancer·neoplasm·male breast carcinoma·breast neoplasm·
* The information provided here is compiled from public sources and is for reference only.
